GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » Net Change in Cash

CohBar (CohBar) Net Change in Cash : $3.32 Mil (TTM As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is CohBar Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

CohBar's Net Change in Cash for the three months ended in Jun. 2023 was $0.80 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was $3.32 Mil.

CohBar Net Change in Cash Historical Data

The historical data trend for CohBar's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar Net Change in Cash Chart

CohBar Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.90 6.84 -9.67 2.10 0.94

CohBar Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 1.33 1.72 -0.54 0.80

CohBar Net Change in Cash Calculation

CohBar's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-10.446+11.525+-0.14+0
=0.94

CohBar's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.803+2.603+0+0
=0.80

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CohBar Net Change in Cash Related Terms

Thank you for viewing the detailed overview of CohBar's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

CohBar (CohBar) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » Net Change in Cash
Comparable Companies
BWV RASP FNCH MNPR AMTI NRSN EMMA CELZ PKTX RGBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025
Website
https://www.cohbar.com
CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.
Executives
Stephanie Tozzo director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret director, officer: Chief Executive Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno officer: CFO, Treasurer and Secretary 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle officer: Chief Executive Officer C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern director, officer: Chief Executive Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025

CohBar (CohBar) Headlines

From GuruFocus

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger -- CWBR, FOCS, KDNY, WTT

By Marketwired • 06-29-2023

CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

By GuruFocusNews GuruFocusNews • 06-25-2022

CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)

By Business Wire • 11-28-2023

CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022

By PurpleRose PurpleRose • 08-01-2022

CohBar to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews • 06-18-2022

CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

By Value_Insider Value_Insider • 10-26-2022

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

By sperokesalga sperokesalga • 06-05-2023

CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

By GuruFocusNews GuruFocusNews • 07-05-2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRNA, AAIC, CWBR, EMBK

By PRNewswire PRNewswire • 05-31-2023

CohBar to Participate at Upcoming Conferences in June 2022

By GuruFocusNews GuruFocusNews • 06-27-2022